Learn more about strategies for safely and effectively administering bispecific antibody therapy. #mmsm tinyurl.com/RMEbispec with Jesus Berdeja, MD and Ajai Chari

March is Multiple Myeloma Awareness Month—the perfect opportunity to make sure your #primarycare care practice is well positioned to help pts with myeloma. Visit here tinyurl.com/MMCMEVRT to learn credit, but don't delay: this activity expires on 3/15 @themmrf Hearn Jay Cho MD, PhD

Time⌛️is running out to get your #mmsm CME

Expiring tomorrow: CME Q&A on BCMA-targeted immunotherapy for myeloma. #mmsm Don't delay: tinyurl.com/RRMMQA #myelomaawarenessmonth

March is Myeloma Action Month - an annual global awareness campaign to raise awareness of Multiple Myeloma. LARVOL remains committed to providing valuable oncology insights to drive progress in cancer research. Here are 5 Multiple Myeloma trials with Anticipated U.S. FDA

Stay current on ATTR-CM care (last call for CME credit expires on April 2, 2025) with Omar AbouEzzeddine MDCM, MS (He/Him/His) and Omar K. Siddiqi, MD, FACC click here 🖱️➡️tinyurl.com/ATTRCMHS

Explore evolving guidelines for metastatic bladder cancer, emerging immunotherapy in muscle-invasive bladder cancer, and real-world patient perspectives on managing AEs in our newest CME activity with Elizabeth Plimack MD & Bladder Cancer Advocacy Network. Click now tinyurl.com/CEminRME

Our roundtable has convened with Dr. Amrita Krishnan, Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 and Zainab Shahid MD, FACP, FIDSA 🇺🇸🇵🇰 as they discuss innovative CD38 antibody quadruplet regimens, which offer the promise of improved depth of response for patients newly diagnosed with multiple myeloma #mmsm mycme.com/courses/newly-…

Check out @themmrf enhanced podcast for expert and patient insights on bispecific antibodies in multiple myeloma. #mmsm with Jesus Berdeja, MD Ajai Chari reachmd.com/programs/proje…

In this activity Jesus Berdeja, MD and Ajai Chari review the unique benefits and risks of bispecific antibodies for myeloma. #mmsm @themmrf Don’t delay: this activity expires on Thursday, May 1. mycme.com/courses/preven…

Explore the latest advancements in bispecific antibody therapy for relapsed/refractory multiple myeloma in Multiple Myeloma RF's episode of Myeloma Matters for clinicians. #mmsm reachmd.com/programs/proje…

Explore how novel therapies are changing bladder cancer care with Elizabeth Plimack MD, Shilpa Gupta, MD, & BladderCancerUS reachmd.com/programs/cme/a…

🔬 1,100+ #myeloma patients. 10+ years of data. The largest clinical-genomic study of its kind: the MMRF CoMMpass℠ Study. It's supported 100+ peer-reviewed papers, and countless abstracts & presentations worldwide. Learn more: ow.ly/nBCB50VOBc9 #NationalCancerResearchMonth

1/3🧵 🔥Hot off the press. ⭐️My co-authors & I are excited to share this just published paper ASCO #ASCO25 #ASCOEdBook on a topic that is near & dear to my heart: ✅“The ART of #Oncology #Education & #Knowledge Sharing. It is All About the “#How” 👇🏻 ascopubs.org/doi/10.1200/ED…

Link to study in @BloodJournal : ashpublications.org/blood/article/…

An U.S. FDA ODAC will be held May 20th to discuss the potential approval for Dara in smoldering myeloma #mmsm Very good points made in the discussion 👇 ➡️ fda.gov/media/186527/d… Few important observations summarised here🧵

The U.S. FDA ODAC recommends approval of daratumumab (Darzalex) for high-risk smoldering myeloma. The MMRF supports access to safe and effective treatments for all patients and research to better define this population. #MultipleMyeloma #theMMRF

From No Hope to a Potential Cure for a Deadly Blood Cancer Gina Kolata #mmsm #ciltacel nytimes.com/2025/06/03/hea…

Designed with a slick, streamlined interface optimized for mobile devices, our newest interactive CME activity on recent advances in RRMM management is now available! Multiple Myeloma RF #mmsm Start here ➡️tinyurl.com/RRMMRMEx

Is your knowledge of bladder cancer care up to date?Our CME-accredited Q-Challenge activity tests your knowledge of—and provides insights on—the latest advances: tinyurl.com/RMDQchl Bladder Cancer Advocacy Network